Immutep taps Charles River for IMP761 LAG-3 antibody preclinical study

Immutep Limited, an Australian biotech company specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, has partnered with Charles River Laboratories to conduct a GLP ... Read More